SCHEMBL16237804

SCHEMBL16237804

O=C(O)c1c(CBr)nc(-c2nccs2)nc1-c1ccc(F)c(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.38
VCP P55072 1/20 0.36
ADORA2A P29274 1/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35
MEN1 O00255 1/20 0.34
HTT P42858 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGDR2 Q9Y5Y4 3/20 0.34
CHEK2 O96017 1/20 0.34
ECE1 P42892 1/20 0.33
KDM5A P29375 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM5B Q9UGL1 1/20 0.33
HDAC2 Q92769 2/20 0.33
SIRT5 Q9NXA8 1/20 0.32
PTPN1 P18031 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16237622 0.91 KMO (0.41) KMOVCPADORA2AABL1BCR
SCHEMBL16237675 0.82 ADORA2A (0.39) VCPADORA2AKMT2APTGDR2ECE1
SCHEMBL16237698 0.81 ADORA2A (0.33) KMOADORA2AECE1EIF4EHDAC3
SCHEMBL16237062 0.81 ECE1 (0.34) ADORA2AECE1EIF4E
SCHEMBL17874029 0.80 SCN9A (0.37) KMOADORA2AABL1KDM4CTRPM4
SCHEMBL16237522 0.80 HDAC3 (0.36) KMOADORA2AKMT2ACHEK2ECE1
SCHEMBL16237487 0.79 HDAC3 (0.43) ADORA2AEIF4ETRPM4HDAC3HDAC1
SCHEMBL16237173 0.79 CTSA (0.41) ADORA2APTGDR2ECE1EIF4ETRPM4
SCHEMBL17064250 0.79 HCRTR1 (0.39) ADORA2AKMT2AECE1
SCHEMBL16236743 0.77 ADORA2A (0.39) ADORA2AABL1BCRPTGDR2ECE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997032-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2016-03-23 EP disclosed
WO-2014184328-A1 6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-11-20 WO disclosed